This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (eHealth) (396) Cancer and Clinical Trials (16)

Published on in Vol 7 , No 7 (2018) :July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/11191, first published .
Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Authors of this article:

Isao Hara 1 Author Orcid Image ;   Shimpei Yamashita 1 Author Orcid Image ;   Satoshi Nishizawa 1 Author Orcid Image ;   Kazuro Kikkawa 1 Author Orcid Image ;   Toshio Shimokawa 2 Author Orcid Image ;   Yasuo Kohjimoto 1 Author Orcid Image
Article Authors Cited by (6) Tweetations (1) Metrics
Isao Hara 1 , MD, PhD ;   Shimpei Yamashita 1 , MD ;   Satoshi Nishizawa 1 , MD, Ph D ;   Kazuro Kikkawa 1 , MD, PhD ;   Toshio Shimokawa 2 , PhD ;   Yasuo Kohjimoto 1 , MD, PhD

1 Department of Urology , Wakayama Medical University , Wakayama , JP

2 Clinical Research Center , Wakayama Medical University , Wakayama , JP

Corresponding Author: